At the Stem Cell Summit on 4/7, Sentien CEO Brian Miller announced that the company’s investigational new drug (IND) application for SBI-101 for the treatment of adult patients with acute [...]
Sentien Biotechnologies was featured on the front page of Medical Device Daily™ on April 7, 2017. In the article, Sentien CEO Brian Miller discusses the company’s recent $12M Series [...]
Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced today that it has closed a $12 million Series A investment round. The [...]
